LGVN — Recent News Coverage
All news mentioning LGVN in ESEN's AI-graded feed
News stories with LGVN as an affected ticker. Each article is graded by ESEN AI for impact level and direction (up/down/flat) on LGVN. See /coverage/LGVN for the 30-day aggregate.
MANILATIMES.NET
·
2026-10-26
HIGH
BULLISH
CORR0.72
Longeveron Announces Updated Results from ELPIS II Phase 2b Clinical Trial Evaluating Laromestrocel as a Potential Treatment for Hypoplastic Left Heart Syndrome (HLHS)
$LGVN
◈ ESEN AI
Longeveron (LGVN) reported positive Phase 2b trial results for laromestrocel in hypoplastic left heart syndrome (HLHS), with a secondary endpoint measuring major adverse cardiac events (MACE) achieving statistical signi…
SEEKINGALPHA.COM
·
2026-08-13
NEUTRAL
NEUTRAL
CORR0.35
Longeveron expects ELPIS II HLHS data in mid-september while cash runway extends into Q4 2026 (NASDAQ:LGVN)
$LGVN
◈ ESEN AI
Longeveron (LGVN) disclosed Q2 2026 earnings guidance centered on near-term clinical catalysts. The company expects interim data from its ELPIS II HLHS (hypoplastic left heart syndrome) trial in mid-September, a key inf…
SEEKINGALPHA.COM
·
2026-08-13
LOW
NEUTRAL
CORR0.15
Longeveron Inc. (LGVN) Q2 2026 Earnings Call Transcript
$LGVN
◈ ESEN AI
Longeveron (LGVN) released its Q2 2026 earnings call transcript, a procedurally scheduled disclosure that provides management commentary on quarterly results already reported. Earnings call transcripts represent routine…
SEEKINGALPHA.COM
·
2026-07-01
LOW
NEUTRAL
CORR0.15
Longeveron Inc. (LGVN) Shareholder/Analyst Call Prepared Remarks Transcript
$LGVN
◈ ESEN AI
Longeveron Inc. (LGVN) conducted a shareholder and analyst call on July 1, 2026, featuring remarks from company leadership including Co-Founder Joshua Hare in his Chief Science Officer capacity. This type of earnings/bu…
EXPLORE OTHER FILTERS